Rebeccamycin Terminated Phase 2 Trials for Recurrent Small Cell Lung Cancer (SCLC) / Extensive-stage Small Cell Lung Cancer (SCLC) / Small Cell Lung Cancer, Limited Stage Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00084487Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy